Jiangsu Jibeier Pharmaceutical Past Earnings Performance
Past criteria checks 3/6
Jiangsu Jibeier Pharmaceutical has been growing earnings at an average annual rate of 19%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 13.3% per year. Jiangsu Jibeier Pharmaceutical's return on equity is 10.5%, and it has net margins of 26.9%.
Key information
19.0%
Earnings growth rate
13.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 13.3% |
| Return on equity | 10.5% |
| Net Margin | 26.9% |
| Next Earnings Update | 26 Nov 2024 |
Recent past performance updates
Jiangsu Jibeier Pharmaceutical's (SHSE:688566) Solid Earnings May Rest On Weak Foundations
Nov 06
Impressive Earnings May Not Tell The Whole Story For Jiangsu Jibeier Pharmaceutical (SHSE:688566)
May 02Recent updates
Jiangsu Jibeier Pharmaceutical's (SHSE:688566) Solid Earnings May Rest On Weak Foundations
Nov 06Even With A 38% Surge, Cautious Investors Are Not Rewarding Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) Performance Completely
Oct 08Does Jiangsu Jibeier Pharmaceutical (SHSE:688566) Deserve A Spot On Your Watchlist?
Oct 01Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) Shares Lagging The Market But So Is The Business
Jul 30Impressive Earnings May Not Tell The Whole Story For Jiangsu Jibeier Pharmaceutical (SHSE:688566)
May 02Revenue & Expenses Breakdown
How Jiangsu Jibeier Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 887 | 239 | 476 | 45 |
| 30 Jun 24 | 876 | 245 | 459 | 45 |
| 31 Mar 24 | 890 | 234 | 472 | 57 |
| 31 Dec 23 | 861 | 219 | 467 | 56 |
| 30 Sep 23 | 845 | 230 | 437 | 55 |
| 30 Jun 23 | 816 | 209 | 438 | 55 |
| 31 Mar 23 | 681 | 164 | 375 | 57 |
| 31 Dec 22 | 655 | 155 | 362 | 55 |
| 30 Sep 22 | 569 | 118 | 337 | 47 |
| 30 Jun 22 | 516 | 101 | 315 | 41 |
| 31 Mar 22 | 528 | 117 | 316 | 31 |
| 31 Dec 21 | 510 | 115 | 303 | 29 |
| 30 Sep 21 | 530 | 127 | 309 | 34 |
| 30 Jun 21 | 574 | 140 | 333 | 34 |
| 31 Mar 21 | 570 | 132 | 332 | 34 |
| 31 Dec 20 | 566 | 130 | 330 | 34 |
| 30 Sep 20 | 543 | 118 | 310 | 32 |
| 30 Jun 20 | 530 | 110 | 301 | 37 |
| 31 Mar 20 | 531 | 114 | 302 | 31 |
| 31 Dec 19 | 543 | 113 | 311 | 31 |
| 31 Dec 18 | 485 | 97 | 284 | 20 |
| 31 Dec 17 | 452 | 78 | 268 | 17 |
| 31 Dec 16 | 444 | 77 | 266 | 17 |
Quality Earnings: 688566 has high quality earnings.
Growing Profit Margin: 688566's current net profit margins (26.9%) are lower than last year (27.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688566's earnings have grown by 19% per year over the past 5 years.
Accelerating Growth: 688566's earnings growth over the past year (3.5%) is below its 5-year average (19% per year).
Earnings vs Industry: 688566 earnings growth over the past year (3.5%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 688566's Return on Equity (10.5%) is considered low.